RU2007133509A - Применение комплексных соединений железа (iii) - Google Patents
Применение комплексных соединений железа (iii) Download PDFInfo
- Publication number
- RU2007133509A RU2007133509A RU2007133509/15A RU2007133509A RU2007133509A RU 2007133509 A RU2007133509 A RU 2007133509A RU 2007133509/15 A RU2007133509/15 A RU 2007133509/15A RU 2007133509 A RU2007133509 A RU 2007133509A RU 2007133509 A RU2007133509 A RU 2007133509A
- Authority
- RU
- Russia
- Prior art keywords
- iron
- iii
- use according
- maltodextrins
- complex compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (8)
1. Применение комплексных соединений железа (III) с углеводами или их производными для получения лекарственного средства для улучшения иммунной защиты и/или деятельности мозга, в котором комплексное соединение железа (III) является железо (III)-полимальтозным комплексным соединением или комплексным соединением железа (III) с продуктом окисления одного или нескольких мальтодекстринов.
2. Применение по п.1, в котором железо(III)-полимальтозное комплексное соединение имеет молекулярную массу в диапазоне от 20000 до 500000 Да.
3. Применение по п.1, в котором комплексное соединение железа (III) с продуктом окисления одного или нескольких мальтодекстринов является растворимьм в воде железо-углеводным комплексом, состоящим из водного раствора соли железа (III) и водного раствора продукта окисления одного или нескольких мальтодекстринов с водным раствором гипохлорита при находящемся в щелочном диапазоне показателе рН, причем при использовании одного мальтодекстрина его декстрозный эквивалент составляет от 5 до 37, при использовании смеси из нескольких мальтодекстринов декстрозный эквивалент смеси составляет от 5 до 37, в декстрозный эквивалент составляющих смесь отдельных мальтодекстринов составляет от 2 до 40.
4. Применение по любому из пп.1-3 для получения лекарственного средства для орального или парентерального введения.
5. Применение по п.1 для получения лекарственного средства для лечения детей, подростков или взрослых.
6. Применение по п.1, в котором лекарственное средство представлено в форме таблетки, водных раствора или эмульсии, в виде гранулята, капсулы, геля или саше.
7. Применение по п.1 для улучшения уровня нейтрофилов, уровня антител и/или функции лимфоцитов, характеризующейся реакцией лимфоцитов на фитогемагглютинин.
8. Применение по п.1 для лечения пациентов с вызываемой дефицитов железа анемией, с дефицитом железа без анемии, а также пациентов без вызываемой дефицитом железа анемии или дефицита железа.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05100907 | 2005-02-09 | ||
| EP05100907.4 | 2005-02-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007133509A true RU2007133509A (ru) | 2009-03-20 |
| RU2359680C2 RU2359680C2 (ru) | 2009-06-27 |
Family
ID=34938674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007133509/15A RU2359680C2 (ru) | 2005-02-09 | 2006-01-18 | Применение комплексных соединений железа (iii) |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8722101B2 (ru) |
| EP (1) | EP1848446B1 (ru) |
| JP (1) | JP5060312B2 (ru) |
| KR (1) | KR20070107106A (ru) |
| CN (1) | CN101155593A (ru) |
| AT (1) | ATE445406T1 (ru) |
| AU (1) | AU2006212322B2 (ru) |
| BR (1) | BRPI0606974A2 (ru) |
| CA (1) | CA2597154C (ru) |
| CR (1) | CR9300A (ru) |
| CY (1) | CY1109685T1 (ru) |
| DE (1) | DE502006005100D1 (ru) |
| DK (1) | DK1848446T3 (ru) |
| ES (1) | ES2333814T3 (ru) |
| HR (1) | HRP20100027T1 (ru) |
| IL (1) | IL185020A (ru) |
| MX (1) | MX2007009588A (ru) |
| NO (1) | NO20074536L (ru) |
| PL (1) | PL1848446T3 (ru) |
| PT (1) | PT1848446E (ru) |
| RU (1) | RU2359680C2 (ru) |
| SI (1) | SI1848446T1 (ru) |
| TN (1) | TNSN07307A1 (ru) |
| UA (1) | UA88347C2 (ru) |
| WO (1) | WO2006084782A1 (ru) |
| ZA (1) | ZA200707716B (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10249552A1 (de) * | 2002-10-23 | 2004-05-13 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
| EP2626074A1 (en) | 2006-01-06 | 2013-08-14 | Luitpold Pharmaceuticals, Inc. | Methods and compositions for administration of iron |
| EP2165713B1 (en) * | 2008-09-19 | 2012-11-14 | Nestec S.A. | Whey and thymus function |
| CA2756580A1 (en) | 2009-03-25 | 2010-09-30 | Hans Andreasen | A stable iron oligosaccharide compound |
| WO2012104204A1 (en) | 2011-01-31 | 2012-08-09 | Vifor (International) Ag | Iron-carbohydrate complex compounds for the intravenous therapy of malaria |
| US11395502B2 (en) * | 2012-10-18 | 2022-07-26 | Patrick Monsivais | Formulation for iron supplements |
| CN105228621A (zh) * | 2013-03-28 | 2016-01-06 | 维福（国际）股份有限公司 | 用于缺铁症状和缺铁性贫血的治疗和预防的Fe(III)络合化合物 |
| KR20150078375A (ko) * | 2013-12-30 | 2015-07-08 | 한화케미칼 주식회사 | 철산화물 나노입자를 포함하는 철결핍증의 예방 또는 치료용 약학 조성물 |
| FR3075001B1 (fr) * | 2017-12-14 | 2021-09-10 | Tereos Starch & Sweeteners Belgium | Utilisation des maltodextrines pour ameliorer la cognition et/ou stimuler le developpement du cerveau |
| CN114288320A (zh) * | 2021-12-29 | 2022-04-08 | 珠海天翼医药技术开发有限公司 | 一种猪用口服补铁剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3076798A (en) | 1961-02-23 | 1963-02-05 | Hausmann Lab Ltd | Process for preparing a ferric hydroxide polymaltose complex |
| US3766165A (en) | 1966-08-17 | 1973-10-16 | Pfizer | Polysaccharides and their preparation |
| DE4421159C1 (de) * | 1994-06-20 | 1995-08-24 | Thomas Bruns | Verwendung von Eisen(III)-oxid (Fe¶2¶O¶3¶) bei Immunschwäche |
| DE19734293A1 (de) * | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
| AU2002220280A1 (en) * | 2000-12-07 | 2002-06-18 | Ad "Zdravlje" Farmaceutsko - Hemijska Industrija, Centar Za Istrazivanje I Razvoj | Polynuclear complex fe(iii) with pullulan oligomers, process of its obtaining, and pharmaceutical preparations on the basis of the complex |
| JP2005510581A (ja) | 2001-04-10 | 2005-04-21 | ダニスコ・ユーエスエー・インコーポレーテッド | モノカルボン酸類およびラクトン類を用いた単糖類および二糖類の重合 |
| DK1492821T3 (da) | 2002-04-09 | 2006-11-27 | Pharmacosmos Holding As | Jerndextrinforbindelser til behandling af jernmangelanæmi |
| DE10249552A1 (de) * | 2002-10-23 | 2004-05-13 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
-
2006
- 2006-01-18 DK DK06707742.0T patent/DK1848446T3/da active
- 2006-01-18 AT AT06707742T patent/ATE445406T1/de active
- 2006-01-18 PL PL06707742T patent/PL1848446T3/pl unknown
- 2006-01-18 CN CNA2006800115263A patent/CN101155593A/zh active Pending
- 2006-01-18 DE DE502006005100T patent/DE502006005100D1/de active Active
- 2006-01-18 ES ES06707742T patent/ES2333814T3/es active Active
- 2006-01-18 EP EP06707742A patent/EP1848446B1/de active Active
- 2006-01-18 WO PCT/EP2006/050276 patent/WO2006084782A1/de active Application Filing
- 2006-01-18 SI SI200630432T patent/SI1848446T1/sl unknown
- 2006-01-18 BR BRPI0606974-6A patent/BRPI0606974A2/pt not_active IP Right Cessation
- 2006-01-18 JP JP2007554530A patent/JP5060312B2/ja not_active Expired - Fee Related
- 2006-01-18 PT PT06707742T patent/PT1848446E/pt unknown
- 2006-01-18 CA CA2597154A patent/CA2597154C/en not_active Expired - Fee Related
- 2006-01-18 UA UAA200708978A patent/UA88347C2/ru unknown
- 2006-01-18 RU RU2007133509/15A patent/RU2359680C2/ru not_active IP Right Cessation
- 2006-01-18 US US11/815,568 patent/US8722101B2/en not_active Expired - Fee Related
- 2006-01-18 AU AU2006212322A patent/AU2006212322B2/en not_active Ceased
- 2006-01-18 MX MX2007009588A patent/MX2007009588A/es active IP Right Grant
- 2006-01-18 KR KR1020077020249A patent/KR20070107106A/ko not_active Application Discontinuation
-
2007
- 2007-08-02 IL IL185020A patent/IL185020A/en not_active IP Right Cessation
- 2007-08-08 TN TNP2007000307A patent/TNSN07307A1/en unknown
- 2007-08-09 CR CR9300A patent/CR9300A/es unknown
- 2007-09-07 NO NO20074536A patent/NO20074536L/no not_active Application Discontinuation
- 2007-09-07 ZA ZA200707716A patent/ZA200707716B/xx unknown
-
2009
- 2009-12-14 CY CY20091101333T patent/CY1109685T1/el unknown
-
2010
- 2010-01-14 HR HR20100027T patent/HRP20100027T1/hr unknown
-
2014
- 2014-03-10 US US14/202,056 patent/US20140187514A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070107106A (ko) | 2007-11-06 |
| IL185020A (en) | 2013-10-31 |
| PT1848446E (pt) | 2009-12-21 |
| ZA200707716B (en) | 2008-06-25 |
| RU2359680C2 (ru) | 2009-06-27 |
| CA2597154A1 (en) | 2006-08-17 |
| JP5060312B2 (ja) | 2012-10-31 |
| US20140187514A1 (en) | 2014-07-03 |
| HRP20100027T1 (hr) | 2010-02-28 |
| PL1848446T3 (pl) | 2010-03-31 |
| WO2006084782A1 (de) | 2006-08-17 |
| DK1848446T3 (da) | 2010-02-15 |
| CY1109685T1 (el) | 2014-08-13 |
| SI1848446T1 (sl) | 2010-01-29 |
| AU2006212322A1 (en) | 2006-08-17 |
| CA2597154C (en) | 2011-03-15 |
| ATE445406T1 (de) | 2009-10-15 |
| MX2007009588A (es) | 2007-09-12 |
| US8722101B2 (en) | 2014-05-13 |
| EP1848446A1 (de) | 2007-10-31 |
| AU2006212322B2 (en) | 2012-01-19 |
| TNSN07307A1 (en) | 2008-12-31 |
| ES2333814T3 (es) | 2010-03-01 |
| JP2008530049A (ja) | 2008-08-07 |
| NO20074536L (no) | 2007-11-05 |
| IL185020A0 (en) | 2007-12-03 |
| US20080214496A1 (en) | 2008-09-04 |
| EP1848446B1 (de) | 2009-10-14 |
| BRPI0606974A2 (pt) | 2009-07-28 |
| DE502006005100D1 (de) | 2009-11-26 |
| CR9300A (es) | 2007-12-07 |
| CN101155593A (zh) | 2008-04-02 |
| UA88347C2 (ru) | 2009-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007133509A (ru) | Применение комплексных соединений железа (iii) | |
| RU2008111148A (ru) | Применение комплексных соединений железа (iii) для производства лекарственного средства для перорального лечения железодефицитных состояний у больных, страдающих хроническими воспалительными заболеваниями кишечника | |
| RU2002106399A (ru) | Составы моксифлоксацина, содержащие поваренную соль | |
| MA34916B1 (fr) | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques | |
| JP7221208B2 (ja) | 抗生物質組成物 | |
| HRP20240168T1 (hr) | Kombinacije dolutegravira i lamivudina za liječenje hiv infekcije | |
| WO2006050581A2 (en) | Betaine as agent against arthropod - or mosquito -borne diseases | |
| SA91120263B1 (ar) | تركيبات ضد الملاريا | |
| JP2009517359A (ja) | 三価鉄錯体およびレドックス活性物質を含有する薬剤 | |
| CN101693037B (zh) | 黄酮苷类化合物在制备治疗疟疾的药物中应用 | |
| CN1973902B (zh) | 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法 | |
| EA201170528A1 (ru) | Производные 1-бутил-2-гидроксиаралкилпиперазина и их применения в качестве лекарственного средства против депрессии | |
| HRP20220691T1 (hr) | Poboljšanja u i u vezi s pripravcima | |
| Bocci et al. | Rational bases for using oxygen-ozonetherapy as a biological response modifier in sickle cell anemia and beta-thalassemia: a therapeutic perspective | |
| JP2003048839A (ja) | 免疫反応性ＮＯ合成を誘導するｉＮＯＳ酵素を刺激する組成剤およびその製造方法 | |
| JPS6333332A (ja) | エイズ・ウイルス増殖抑制剤 | |
| CN101693036B (zh) | 蔓生白薇苷c在制备治疗疟疾药物中的应用 | |
| RU2217138C1 (ru) | Состав "витализин-2" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний | |
| JP2007314440A (ja) | 体力増強剤 | |
| RU2217141C1 (ru) | Состав "витализин-1" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний | |
| RU2480222C2 (ru) | Фармацевтические препараты, содержащие хелат бисглицинат железа (2) | |
| RU2454234C1 (ru) | Соли 1,3-диэтилбензимидазолия - иммуностимулирующие средства и фармацевтические композиции на их основе | |
| CN101544690A (zh) | 从墨草(P.octandra)所提取的一类植物蛋白、其制备方法及用途 | |
| RU2003108517A (ru) | Способ лечения колибактериоза и сальмонеллеза у поросят | |
| JP2011020938A (ja) | 抗インフルエンザウイルス剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160119 |